INT0036

**INT0036** is an oral thin-film (buccal) formulation of **loxapine**, a dopamine D2 receptor antagonist, developed by **IntelGenx Corp.** using their proprietary **VersaFilm™** technology for the treatment of **schizophrenia**. The technology enables buccal administration, potentially offering faster onset of action, improved bioavailability by bypassing first-pass metabolism, and easier use for patients with swallowing difficulties. A pilot clinical study completed in 2014 demonstrated successful buccal delivery and absorption, confirming the formulation's potential for rapid systemic exposure.

Brand names

Loxapine VersaFilm

Other names

Loxapine oral thin filmLoxapine buccal film